KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to -$79.4 million.

  • Acadia Pharmaceuticals' Cash from Investing Activities rose 376.56% to -$79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$124.5 million, marking a year-over-year increase of 1861.67%. This contributed to the annual value of -$30.5 million for FY2024, which is 19543.72% down from last year.
  • Acadia Pharmaceuticals' Cash from Investing Activities amounted to -$79.4 million in Q3 2025, which was up 376.56% from -$43.3 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Cash from Investing Activities high stood at $192.5 million for Q1 2023, and its period low was -$194.3 million during Q2 2023.
  • Its 5-year average for Cash from Investing Activities is -$12.8 million, with a median of -$17.2 million in 2021.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Cash from Investing Activities surged by 3530172.91% in 2024, and later tumbled by 78360.28% in 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $71.5 million in 2021, then plummeted by 124.81% to -$17.7 million in 2022, then soared by 98.04% to -$347000.0 in 2023, then surged by 35301.73% to $122.2 million in 2024, then plummeted by 164.96% to -$79.4 million in 2025.
  • Its last three reported values are -$79.4 million in Q3 2025, -$43.3 million for Q2 2025, and -$124.0 million during Q1 2025.